New Jersey Alliance for Clinical Translational Science: NJ ACTS

新泽西临床转化科学联盟：NJ ACTS

• 批准号: 10201004
• 负责人: Reynold Alexander Panettieri
• 金额: $ 148.2万
• 依托单位: RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-11 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10201004
• 关键词: AIDS/HIV problem; Address; Affect; Age; Asian Indian; Behavioral; Biometry; Child; Chronic Disease; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Design; Cohort Studies; Collaborations; Communities; Cuban; Databases; Dental; Development; Diagnosis; Diagnostic; Discipline of Nursing; Disease Management; Diverse Workforce; Elderly; Electronic Health Record; Evaluation; Fluorescent in Situ Hybridization; Fostering; Foundations; Government; Growth; Health; Health Insurance Portability and Accountability Act; Health Sciences; Health system; Healthcare; Hospitals; Image; Improve Access; Individual; Industry; Informatics; Infrastructure; Institutes; Institutional Review Boards; Intervention; Investigation; Investments; Laboratories; Leadership; Life Style; Link; Location; Longevity; Low income; Machine Learning; Medicaid; Medical; Mentors; Methodology; Methods; Minority; Minority Groups; Mission; Muslim population group; Neighborhood Health Center; New Jersey; Not Hispanic or Latino; Ontology; Oral health; Outpatients; Parents; Participant; Pathogenesis; Patient Recruitments; Perception; Population; Population Density; Precision therapeutics; Prediction of Response to Therapy; Preventive Intervention; Process; Public Health; Public Health Schools; Recording of previous events; Research; Research Personnel; Research Training; Resources; School Nursing; Science; Solid; South Asian; Special Populations Research; Substance abuse problem; Technology; Therapeutic; Therapeutic Intervention; Training; Translational Research; Universities; Vision; Workforce Development; analytical tool; base; biomarker discovery; career development; catalyst; clinical care; clinical database; clinical investigation; cognitive neuroscience; cohesion; community based participatory research; disease heterogeneity; ethnic diversity; ethnic minority population; follower of religion Jewish; improved; industry partner; innovation; interdisciplinary approach; logarithm; medical schools; member; natural language; next generation; novel; novel strategies; population health; programs; racial diversity; racial minority; recruit; relating to nervous system; research clinical testing; response; severe mental illness; skills; success; tool; translational scientist; treatment response; trial design

Contact PD/PI: Panettieri, Reynold Alexander Project Summary/Abstract Overview Coordinated by Rutgers Biomedical and Health Sciences (RBHS), the New Jersey Alliance for Clinical and Translational Science (NJ ACTS) comprises a consortium with Rutgers and Princeton Universities (PU), NJ Institute for Technology (NJIT), medical, nursing, dental and public health schools, hospitals, community health centers, outpatient practices, industry, policymakers and health information exchanges. All Alliance universities and affiliates have provided substantial resources and contributed to the planning, development and leadership of the consortium. With access to ~7 million people, NJ ACTS serves as a ‘natural laboratory’ for translational and clinical research. With a state population of ~9 million, New Jersey ranks 11th in the US, 1st in population density and higher than average in racial and ethnic diversity. Surprisingly, NJ has no CTSA Hub to coordinate translational and clinical research. Our CTSA Hub focuses on two overarching themes: the heterogeneity of disease pathogenesis and response to treatment, and the value of linking large clinical databases with interventional clinical investigations to identify cause-and-effect and predict therapeutic responses. NJ ACTS will provide: innovative approaches to link information from large databases and electronic health records to inform clinical trial design, execution and analysis; and novel platforms for biomarker discovery using fluorescence in situ hybridization and machine learning to identify unique neural signatures of chronic illness. NJ ACTS will access a large health system with significant member diversity; a rich legacy of community engagement and community-based research platforms; and proven approaches to enhance workforce development in clinical research. With a substantial investment in streamlining research administration and IRB practices at Rutgers and with the inception of NJ ACTS, there exists an unparalleled opportunity for logarithmic growth in clinical research in New Jersey. To build our capacity for participant and clinical interactions as a CTSA Hub, the newly established Trial Accelerator and Recruitment Office will coordinate feasibility assessment, implementation, recruitment, and evaluation of clinical studies. Additionally, our organization of five clinical research units into a cohesive network provides extraordinary expertise in strategic locations to enhance participant recruitment from diverse communities with a particular focus on: children; the elderly; those with serious mental illness or substance abuse issues; low-income individuals served by Medicaid; those with HIV/AIDS; and people of all ages who are minorities, underserved, and victims of health and environmental disparities. With a history of collaboration, partners and affiliates share unique skills, expertise, training and mentoring capabilities that will be greatly amplified within the infrastructure of a CTSA Hub. Princeton and NJIT, without medical schools or hospital affiliates, seeks collaboration with Rutgers to provide clinical research platforms; Rutgers seeks the PU and NJIT expertise in novel informatics platforms, expertise in natural language and ontology, machine learning and cognitive neurosciences. Together NJ ACTS will provide an alliance that will catalyze clinical research and training across New Jersey to improve population health and contribute to the CTSA Consortium. In this revised application, the overall themes remain unchanged but Cores leadership and direction has been markedly refined. Page 337 Project Summary/Abstract Contact PD/PI: Panettieri, Reynold Alexander New Jersey Alliance for Clinical and Translational Science (NJ ACTS)

联系PD/PI：Panettieri，Reynold Alexander 项目摘要/摘要 概述 由罗格斯生物医学和健康科学(RBHS)、新泽西州临床和医疗联盟协调 翻译科学(NJ ACTS)由一个与罗格斯大学和普林斯顿大学(PU)组成的联盟组成 理工学院、医学、护理、牙科和公共卫生学校、医院、社区卫生 中心、门诊、行业、政策制定者和健康信息交流。所有联盟大学 和附属机构提供了大量资源，并为规划、发展和领导做出了贡献 财团的成员。新泽西州ACTS拥有约700万人的访问量，是翻译的天然实验室 和临床研究。新泽西州人口约900万，在美国排名第11，人口第一 人口密度高，种族和民族多样性高于平均水平。令人惊讶的是，新泽西州没有CTSA枢纽需要协调 翻译和临床研究。我们的CTSA中心专注于两个主要主题： 疾病发病机制和治疗反应，以及将大型临床数据库与 介入性临床研究，以确定因果关系和预测治疗反应。《新泽西州法案》将 提供：创新的方法，将来自大型数据库和电子健康记录的信息链接起来，以便 临床试验设计、实施和分析；以及利用荧光光谱发现生物标记物的新平台 原位杂交和机器学习来识别慢性疾病的独特神经特征。《新泽西州法案》将 访问具有显著成员多样性的大型卫生系统；丰富的社区参与和 以社区为基础的研究平台；以及经过验证的加强临床劳动力发展的方法 研究。在简化罗格斯大学的研究管理和IRB实践方面进行了大量投资 随着NJ ACTS的开始，临床上存在着一个无与伦比的对数增长机会 新泽西州的研究。为了建设我们作为CTSA中心的参与者和临床互动的能力，新的 已建立的试验加速器和招募办公室将协调可行性评估、实施、 临床研究的招募和评估。此外，我们将五个临床研究单位组织成一个 凝聚力网络在战略位置提供卓越的专业知识，以增强参与者的招募 不同的社区，特别关注：儿童、老年人、患有严重精神疾病或 药物滥用问题；接受医疗补助的低收入个人；艾滋病毒/艾滋病患者；以及所有人 少数群体，服务不足，是健康和环境差异的受害者。有一段历史 协作、合作伙伴和附属公司共享独特的技能、专业知识、培训和指导能力，将 在CTSA集线器的基础设施中得到极大的放大。普林斯顿和NJIT，没有医学院或 医院附属公司寻求与罗格斯大学合作提供临床研究平台；罗格斯大学寻求PU 以及NJIT在新型信息学平台、自然语言和本体、机器学习方面的专业知识 和认知神经科学。NJ ACTS将共同提供一个联盟，将催化临床研究和 在新泽西州各地进行培训，以改善人口健康，并为CTSA联盟做出贡献。在本修订版中 在应用方面，总体主题保持不变，但核心领导和方向已明显细化。 第337页 项目摘要/摘要 联系PD/PI：Panettieri，Reynold Alexander 新泽西临床和翻译科学联盟(新泽西州ACTS)